Octagon Capital Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Octagon Capital Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-199,417	Closed	-$16.6M	–	43
2022 Q4	$16.6M	Sell	199,417 -43,983	-18%	-$3.56M	2.58%	11
2022 Q3	$19.3M	Hold	243,400	–	–	3.33%	8
2022 Q2	$18.1M	Buy	243,400 +187,600	+336%	+$14.1M	4.82%	7
2022 Q1	$5.01M	Buy	+55,800	New	+$5.15M	1.08%	20

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Octagon Capital Advisors's XBI Position: Q1 2023 in Review

Octagon Capital Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2023, closing a stake of 199,417 shares — an estimated $16.6M sold.

Octagon Capital Advisors first reported a position in XBI in Q1 2022 and held it in 4 quarters. The position peaked at $19.3M in Q3 2022. 713 funds tracked by Wall St. Rank hold XBI as of Q1 2023.

Octagon Capital Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2023 after selling out during the quarter.
Octagon Capital Advisors sold 199,417 State Street SPDR S&P Biotech ETF shares in Q1 2023, an estimated $16.6M.
Octagon Capital Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and held it in 4 quarters.
Octagon Capital Advisors's State Street SPDR S&P Biotech ETF position peaked at $19.3M in Q3 2022.
713 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2023.

Based on Octagon Capital Advisors's 13F filing for Q1 2023, filed 15 May 2023.